Presentation is loading. Please wait.

Presentation is loading. Please wait.

Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group 

Published byAlban George Modified over 6 years ago

Similar presentations

Presentation on theme: "Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group "— Presentation transcript:

1 Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group  Guénaëlle Levallet, PhD, Mélissa Vaisse-Lesteven, MSc, Nolwenn Le Stang, MS, Anabelle Gilg Soit Ilg, MD, Patrick Brochard, MD, Philippe Astoul, MD, Jean Claude Pairon, MD, Emmanuel Bergot, MD, Gérard Zalcman, MD, PhD, Francoise Galateau-Sallé, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 3, Pages (March 2012) DOI: /JTO.0b013e da5 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Representative intensity of c-MET or phospho-c-MET immunostaining in malignant pleural mesothelioma (MPM). MPM tumors were stained with anti-c-MET (upper panels) or phospho-c-MET (lower panels) antibody as described in the “Patients and Methods” section. Pictures illustrate representative intensities: weak (I1), moderate (I2), and strong (I3) measured. Internal positive controls were normal epithelial cells. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e da5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Representative subcellular localization of phospho-c-MET immunostaining in malignant pleural mesothelioma (MPM). MPM tumors were stained with antiphospho-c-MET antibody as described in the “Patients and Methods” section. Pictures illustrate representative subcellular localization observed. Internal positive controls were normal epithelial cells. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e da5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 c-MET subcellular localization according its immunostaining intensity. Malignant pleural mesothelioma (MPM) tumors were stained with anti-c-MET antibody as described in the “Patients and Methods” section. For each intensity, set of histogram represent percentage of case number counted in each subcellular compartment. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e da5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Nuclear translocation of phospho-c-MET in HBEC3 cells under hepatocyte growth factor (HGF) stimulation. HBEC3 cells were cultivated for 24 hours in KSFM devoid of EGFr and BPE, then stimulated 5, 10, 15, or 20 minutes with HGF (40 ng/ml) or not. A, Confocal laser scanning images of HBEC3 cells stained for c-MET, phospho-c-MET, or alpha-tubulin followed by a Texas-red-conjugated secondary antibody. Scale bar = 50 μm. B, Representative Western blot performed with antiphospho-c-MET antibody (see Patients and Methods section) and its analyses. Ratios of phospho-c-MET expression compared with the normalizer of each fraction were determined in three separate cultures. Values are mean ± SEM. Positive control is extract from H1975 cell line. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e da5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

6 Figure 5 c-MET intensity staining (IS) relationship with overall survival rate. The overall survival rate curve for the 157 patients from the MESOPATH group is presented according to c-MET intensity staining expression. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e da5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

7 Figure 6 c-MET subcellular localization relationship with overall survival rate. The overall survival rate curve for the 157 patients from the MESOPATH group is presented according to c-MET subcellular localization. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e da5) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group "

Similar presentations

Alpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non–Small Cell Lung Cancer  Ming-Chuan Wang, PhD, Ying-Hua Chang,

Alpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non–Small Cell Lung Cancer  Ming-Chuan Wang, PhD, Ying-Hua Chang,
Epidemiology of Environmental Exposure and Malignant Mesothelioma

Epidemiology of Environmental Exposure and Malignant Mesothelioma
Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas  Noémie Leblay,

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas  Noémie Leblay,
Deregulation of SLIT2-Mediated Cdc42 Activity Is Associated with Esophageal Cancer Metastasis and Poor Prognosis  Ruo-Chia Tseng, PhD, Jia-Ming Chang,

Deregulation of SLIT2-Mediated Cdc42 Activity Is Associated with Esophageal Cancer Metastasis and Poor Prognosis  Ruo-Chia Tseng, PhD, Jia-Ming Chang,
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies  Sandra Salvi, PhD, Serena Varesano, PhD, Simona.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
RET Mutation and Expression in Small-Cell Lung Cancer

RET Mutation and Expression in Small-Cell Lung Cancer
Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages  Anne-Laure Chéné, MD,

Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages  Anne-Laure Chéné, MD,
Epidemiology of Environmental Exposure and Malignant Mesothelioma

Epidemiology of Environmental Exposure and Malignant Mesothelioma
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Identifying Inhibitors of Epithelial-Mesenchymal Transition by Connectivity Map–Based Systems Approach  Ajaya Kumar Reka, PhD, Rork Kuick, MS, Himabindu.

Identifying Inhibitors of Epithelial-Mesenchymal Transition by Connectivity Map–Based Systems Approach  Ajaya Kumar Reka, PhD, Rork Kuick, MS, Himabindu.
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma  Valentina Pinelli, MD, Sophie.

Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma  Valentina Pinelli, MD, Sophie.
Alpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non–Small Cell Lung Cancer  Ming-Chuan Wang, PhD, Ying-Hua Chang,

Alpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non–Small Cell Lung Cancer  Ming-Chuan Wang, PhD, Ying-Hua Chang,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival  Zarah Glad.

Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival  Zarah Glad.
MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity 

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity 

Similar presentations

Ads by Google